News Room

Plexus Ventures Has Been Appointed to Assist Mabion S.A. and SIFI S.p.A

December 20, 2018

Philadelphia, Pennsylvania – Plexus Ventures LLC has been appointed to assist Mabion S.A. to secure co-development partners for its portfolio of biosimilar candidates in the fields of oncology, autoimmune and ophthalmology. Mabion is a publicly held biotechnology company based in Poland. It was established in 2007 to introduce the latest generation of drugs based on humanized monoclonal antibodies. Mabion’s lead biosimilar, MabionCD20, has been submitted for review by the European Medicines Agency.

Plexus Ventures has also been appointed to assist SIFI S.p.A with its corporate development and geographic expansion strategy. SIFI, the leading Italian ophthalmic company, has been focused on eye care since its foundation in 1935, featuring an integrated business model, from research & development to manufacturing and commercialization both in the pharmaceutical and biomedical sectors. SIFI concentrates its R&D and manufacturing in Italy and has commercial subsidiaries in Romania, Spain and Mexico. Additionally, SIFI markets its products in more than 20 countries through distributors.

About Plexus Ventures

Now in its 29th year, Plexus Ventures provides strategic advice, business development and alliance management services to clients in the pharmaceutical, consumer healthcare and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Barcelona, Basel, Beijing, Indianapolis, London, Los Angeles, Milan, Oxford, Philadelphia and Tokyo, Plexus Ventures possesses the capabilities to effectively serve clients in North America, South America, Europe and Asia. Plexus Ventures is both well-known and well respected by leading pharmaceutical and consumer healthcare companies worldwide.